Literature DB >> 28395886

Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.

Wesley T O'Neal1, Pratik Sandesara2, Muhammad Hammadah2, Sanjay Venkatesh3, Ayman Samman-Tahhan2, Heval M Kelli2, Elsayed Z Soliman4.   

Abstract

Atrial fibrillation (AF) is associated with an increased risk for adverse events in patients with heart failure with preserved ejection fraction (HFpEF), but it is currently unknown if gender differences in these outcomes exist. To explore this hypothesis, we examined gender differences in the associations of AF with adverse outcomes in 3,385 (mean age 69 ± 9.6 years, 49% male, 89% white) patients with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Baseline AF cases were identified by self-reported history, medical record review, and baseline electrocardiogram data. Outcomes were adjudicated by a clinical end point committee and included the following: hospitalization, hospitalization for heart failure, stroke, death, and cardiovascular death. Cox regression was used to examine the risk of each outcome associated with AF. Over a median follow-up of 3.4 years, AF was associated with an increased risk for hospitalization (hazard ratio [HR] 1.49, 95% confidence interval [CI] 1.34 to 1.66), hospitalization for heart failure (HR 1.49, 95% CI 1.23 to 1.81), stroke (HR 2.10, 95% CI 1.43 to 2.09), death (HR 1.22, 95% CI 1.02 to 1.47), and cardiovascular death (HR 1.31, 95% CI 1.04 to 1.65). The association between AF and hospitalization was stronger in women (HR 1.63, 95% CI 1.40 to 1.91) than men (HR 1.37, 95% CI 1.18 to 1.58; p-interaction = 0.032). Although significant interactions were not observed for the other outcomes, we appreciated that the risk estimates were higher for women compared with men. In conclusion, AF increases the risk for adverse cardiovascular outcomes in patients with HFpEF, and the presence of this arrhythmia in women possibly is associated with a greater risk for adverse events than men.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28395886      PMCID: PMC5423833          DOI: 10.1016/j.amjcard.2017.02.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Christian Torp-Pedersen; Morten Lock Hansen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2012-04-03       Impact factor: 5.249

2.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

Review 3.  Epidemiology and clinical course of heart failure with preserved ejection fraction.

Authors:  Carolyn S P Lam; Erwan Donal; Elisabeth Kraigher-Krainer; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

4.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

Authors:  Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer
Journal:  Am Heart J       Date:  2011-11-08       Impact factor: 4.749

5.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

Review 6.  The emerging epidemic of heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Jonathan D Rich; Sanjiv J Shah
Journal:  Curr Heart Fail Rep       Date:  2013-12

7.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Authors:  Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-04-27       Impact factor: 24.094

8.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

9.  Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study).

Authors:  Jens Friberg; Henrik Scharling; Niels Gadsbøll; Thomas Truelsen; Gorm B Jensen
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

10.  Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction.

Authors:  David D McManus; Grace Hsu; Sue Hee Sung; Jane S Saczynski; David H Smith; David J Magid; Jerry H Gurwitz; Robert J Goldberg; Alan S Go
Journal:  J Am Heart Assoc       Date:  2013-02-01       Impact factor: 5.501

View more
  9 in total

Review 1.  Gender Differences in Arrhythmias: Focused on Atrial Fibrillation.

Authors:  Xiao-Ting Tian; Ying-Jia Xu; Yi-Qing Yang
Journal:  J Cardiovasc Transl Res       Date:  2019-10-21       Impact factor: 4.132

2.  Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-05-28       Impact factor: 3.327

Review 3.  The imminent epidemic of atrial fibrillation and its concomitant diseases - Myocardial infarction and heart failure - A cause for concern.

Authors:  Christin S Börschel; Renate B Schnabel
Journal:  Int J Cardiol       Date:  2018-11-30       Impact factor: 4.164

Review 4.  Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies.

Authors:  Marijana Tadic; Cesare Cuspidi; Sven Plein; Evgeny Belyavskiy; Frank Heinzel; Maurizio Galderisi
Journal:  J Clin Med       Date:  2019-06-04       Impact factor: 4.241

5.  New Discovery of Left Atrial Macroreentry Tachycardia: Originating from the Spontaneous Scarring of Left Atrial Anterior Wall.

Authors:  Xuefeng Zhu; Hongxia Chu; Jianping Li; Chunxiao Wang; Wenjing Li; Zhen Wang; Zhiyuan Xu; Yanyan Jing; Ruifu Zhao; Lin Zhong; Naibao Hu
Journal:  J Interv Cardiol       Date:  2021-12-15       Impact factor: 2.279

Review 6.  Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction.

Authors:  Heidi Budde; Roua Hassoun; Andreas Mügge; Árpád Kovács; Nazha Hamdani
Journal:  Front Physiol       Date:  2022-07-07       Impact factor: 4.755

7.  Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia.

Authors:  Abdullah Abdulfattah Mashat; Ahmed Hussein Subki; Moaz Abdulrahman Bakhaider; Wejdan Mohammad Baabdullah; Jawaher Badr Walid; Abdulrahman Hatim Alobudi; Maged Mazen Fakeeh; Anas Jamal Algethmi; Wesam Awad Alhejily
Journal:  Int J Gen Med       Date:  2019-01-11

8.  Sex Differences in Heart Failure With Preserved Ejection Fraction.

Authors:  Yohei Sotomi; Shungo Hikoso; Daisaku Nakatani; Hiroya Mizuno; Katsuki Okada; Tomoharu Dohi; Tetsuhisa Kitamura; Akihiro Sunaga; Hirota Kida; Bolrathanak Oeun; Taiki Sato; Sho Komukai; Shunsuke Tamaki; Masamichi Yano; Takaharu Hayashi; Akito Nakagawa; Yusuke Nakagawa; Yoshio Yasumura; Takahisa Yamada; Yasushi Sakata
Journal:  J Am Heart Assoc       Date:  2021-02-23       Impact factor: 5.501

Review 9.  Sex differences in acute cardiovascular care: a review and needs assessment.

Authors:  Saraschandra Vallabhajosyula; Dhiran Verghese; Viral K Desai; Pranathi R Sundaragiri; Virginia M Miller
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.